Dare Bioscience (NASDAQ:DARE) released its quarterly earnings data on Wednesday. The biotechnology company reported ($0.29) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.09), Fidelity Earnings reports.
Shares of DARE traded down $0.04 on Thursday, hitting $0.76. The company’s stock had a trading volume of 1,879 shares, compared to its average volume of 203,861. The firm has a market capitalization of $13.03 million, a P/E ratio of -0.71 and a beta of 1.96. Dare Bioscience has a fifty-two week low of $0.60 and a fifty-two week high of $3.25. The business has a 50 day moving average price of $0.80.
A number of equities research analysts have weighed in on DARE shares. ValuEngine raised Dare Bioscience from a “hold” rating to a “buy” rating in a report on Tuesday, July 2nd. Maxim Group reaffirmed a “buy” rating and set a $3.00 price objective on shares of Dare Bioscience in a report on Thursday, May 16th.
Daré Bioscience, Inc, a clinical-stage biopharmaceutical company, focuses on developing and marketing women's reproductive health products in the United States. The company intends to develop therapies in the areas of contraception, vaginal health, sexual health, and fertility. Its product candidates include Ovaprene, a non-hormonal monthly contraceptive; and SST-6007, a topical sildenafil cream for female sexual arousal disorder.
Recommended Story: Street Name
Receive News & Ratings for Dare Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dare Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.